gdf15 duo set elisa kit  (R&D Systems)

Journal: Radiation Oncology (London, England)

Article Title: Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

doi: 10.1186/s13014-024-02546-y

Figure Lengend Snippet: Distribution of baseline plasma GDF15 levels. (A) Distribution of individual baseline GDF15 levels for all patients. (B) Comparison of baseline GDF15 levels between the concurrent chemo-radiotherapy (cCRT) and the cCRT + metformin arms (Wilcoxon rank sum test p = 0.44: [median = 963.5pg/ml (475.98-2072.85pg/ml) vs. 1094.2pg/ml (417.23-2444.59pg/ml), respectively]

Article Snippet: Assays were performed using the GDF15 Duo Set ELISA kit (Catalog #DY957, R&D Systems).

Techniques: Clinical Proteomics, Comparison

Journal: Radiation Oncology (London, England)

Article Title: Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

doi: 10.1186/s13014-024-02546-y

Figure Lengend Snippet: Modulation of plasma GDF15 levels by treatments. Levels of GDF15 over the first 26 weeks (6 months) from initiation of cCRT (assessments on weeks 1, 6 and 26 of cCRT or weeks 3, 8 and 26 of metformin treatment). (A) For all patients included in this analysis. (B) For patients based on treatment arm (cCRT: Control, cCRT + Metformin: Metformin). Statistical significance compared to average baseline plasma GDF15 levels, * p < 0.05, ** p < 0.01, *** p < 0.001. Statistical significance compared to average plasma GDF15 level of the Control (cCRT) arm patients at the same timepoint: # p < 0.05, ## p < 0.01

Article Snippet: Assays were performed using the GDF15 Duo Set ELISA kit (Catalog #DY957, R&D Systems).

Techniques: Clinical Proteomics, Control

Journal: Radiation Oncology (London, England)

Article Title: Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

doi: 10.1186/s13014-024-02546-y

Figure Lengend Snippet: Association of plasma GDF15 with tumor volumes. (A) Correlation of baseline GDF15 levels with gross tumor volume (GTV). (B) Correlation of circulating GDF15 levels at the end of week 1 of concurrent chemoradiotherapy (cCRT) with planned tumor volume (PTV).

Article Snippet: Assays were performed using the GDF15 Duo Set ELISA kit (Catalog #DY957, R&D Systems).

Techniques: Clinical Proteomics

Journal: Radiation Oncology (London, England)

Article Title: Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

doi: 10.1186/s13014-024-02546-y

Figure Lengend Snippet: Kaplan-Meier survival curves of overall (OS) and relapse free (RFS) survival in relation to baseline GDF15 levels for the entire population. A . OS and B . RFS of patients based on baseline GDF15 levels (black line: below the median of the entire population; red dotted line: above the median). C . Overall survival (OS) of patients based on baseline GDF15 levels using the cutoff value of 1465pg/ml reported by Liu et al. (2016)

Article Snippet: Assays were performed using the GDF15 Duo Set ELISA kit (Catalog #DY957, R&D Systems).

Techniques:

Journal: Radiation Oncology (London, England)

Article Title: Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

doi: 10.1186/s13014-024-02546-y

Figure Lengend Snippet: Prognostic value of baseline GDF15 compared to tumor volume and stage factors ( Univariate analysis ). Hazard Ratio (HR), confidence interval (95% CI) and p-values are illustrated for relapse free (RFS) and overall (OS) survival

Article Snippet: Assays were performed using the GDF15 Duo Set ELISA kit (Catalog #DY957, R&D Systems).

Techniques: